Results 211 to 220 of about 1,095,554 (340)

Hallmarks of Neuroblastoma—Pathophysiology, Diagnosis, and Therapeutic Interventions

Cancer Nexus, EarlyView.
ABSTRACT Neuroblastoma, the most common extracranial solid tumor in childhood, continues to challenge clinicians and researchers because of its heterogeneous nature and complex pathophysiology. Recent breakthroughs in molecular profiling revealed intricate genetic alterations driving tumor progression, necessitating an updated perspective on the ...
Abhimanyu Thakur, Anne Dijkstra
wiley   +1 more source

A Case of Bronchial Artery Aneurysm Incidentally Discovered as a Pulsatile Oesophageal Submucosal Mass. [PDF]

Respirol Case Rep
Kosai I, Kawashima M, Sato K, Wada T, Takeda K, Kato T, Igei H, Masuda K, Morio Y, Matsui H.   +9 more
europepmc   +1 more source

Safety, Tolerability, and Pharmacokinetics of Donanemab in Healthy Chinese Participants: A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Alzheimer's disease (AD), characterized by β‐amyloid (Aβ) plaques and neurofibrillary tangles, is the leading cause of dementia globally. Donanemab is a humanized immunoglobulin G1 in development as a treatment to slow AD progression. This study aimed to evaluate the safety, tolerability, pharmacokinetics (PKs), and immunogenicity of donanemab
Junyu Xu, Nan Zhao, Yihui Wang, Ivelina Gueorguieva, Chenxi Qian, Yimin Cui   +5 more
wiley   +1 more source

Circulating miRNA-375 as a potential novel biomarker for active Kaposi’s sarcoma in AIDS Patients [PDF]

, 2019
Adriana Mattiolo, Angela Grassi, Anna Maria Cattelan, Lisa Gianesello, Lolita Sasset, Maria Assunta Piano, Maria Luisa Calabrò, Paola Zanovello   +7 more
core   +1 more source

R factors in bacteria causing asymptomatic urinary infection in antenatal patients. [PDF]

, 1971
Elizabeth J. Shaw
openalex   +1 more source

First‐in‐Human Phase 1 Study to Evaluate the Clinical Pharmacology Properties of RBN‐3143, a Novel Inhibitor of Mono‐Adenosine Diphosphate Ribosyltransferase‐PARP14

Clinical Pharmacology in Drug Development, EarlyView.
Abstract RBN‐3143 is an inhibitor of PARP14 in development for inflammatory diseases. Multiple assessments were conducted to evaluate the clinical pharmacology properties of RBN‐3134. A randomized, double‐blind, placebo‐controlled study assigned healthy volunteers (HVs) to single ascending doses (SADs) (25‐1000 mg) or multiple ascending doses (MADs ...
Thomas M. Polasek, Alexandra Cole, Viviana Bozón, Erika Manyak, Jonathan Novak, Barbara Yang, Briohny A. Johnston, Sudha Parasuraman, Kushal J. Paneliya, Virna Schuck   +9 more
wiley   +1 more source

Vitamin D status in children with mild, moderate, or severe confirmed COVID-19: systematic-review and meta-analysis. [PDF]

Front Pediatr
Mousavi T, Moosazadeh M.
europepmc   +1 more source

Biochemical, histological, and serological investigations in asymptomatic carriers of Australia antigen. [PDF]

, 1973
David M. Goldberg, R I Russell, J. Garrott Allen, R. N. M. MacSween, John Wallace   +4 more
openalex   +1 more source

First‐in‐Human Single and Multiple Ascending Dose Studies of Balinatunfib, a Small Molecule Inhibitor of TNFR1 Signaling in Healthy Participants

Clinical Pharmacology &Therapeutics, EarlyView.
Oral small molecule inhibitors of tumor necrosis factor alpha (TNFα) are emerging as attractive therapeutic agents for the treatment of various autoimmune diseases. Balinatunfib (SAR441566), a novel oral inhibitor of tumor necrosis factor receptor 1 (TNFR1) signaling, changes the configuration of the soluble TNFα (sTNFα) trimer and prevents its ...
Nassr Nassr, Faiza Rharbaoui, Dietmar Weitz, Johann Gassenhuber, Markus Rehberg, Markus Kohlmann, Fabienne Schumacher, Amel Lahmar, Andreas Kovar, Laurent Perrin, Frank‐Dietrich Wagner, Maria Wiekowski, Mai Anh Nguyen   +12 more
wiley   +1 more source

Time sequence of autoimmune processes in the trajectory to rheumatoid arthritis development: what do we know? [PDF]

RMD Open
Heutz JW, Toes REM, van der Helm-van Mil AHM.   +2 more
europepmc   +1 more source